Detalhe da pesquisa
1.
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
N Engl J Med
; 374(7): 625-35, 2016 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26644172
2.
Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome.
Clin Chem
; 63(7): 1214-1226, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28515099
3.
Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia.
Clin Trials
; 14(6): 563-571, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743191
4.
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
N Engl J Med
; 369(11): 999-1010, 2013 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23991622
5.
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Pediatr Blood Cancer
; 63(2): 299-305, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26402148
6.
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
J Thromb Thrombolysis
; 42(3): 369-75, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27165280
7.
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Platelets
; 27(3): 191-5, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26270719
8.
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
J Pediatr Hematol Oncol
; 37(1): 1-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25493452
9.
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Platelets
; 26(5): 474-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25140584
10.
Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.
Br J Haematol
; 184(6): 1058-1061, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29676449
11.
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
J Thromb Thrombolysis
; 38(2): 127-36, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24043374
12.
Platelet activation and inhibition in sickle cell disease (pains) study.
Platelets
; 25(1): 27-35, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-23469943
13.
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Br J Clin Pharmacol
; 75(6): 1433-44, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23171128
14.
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Platelets
; 24(1): 15-25, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-22372531
15.
Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes.
Haematologica
; 97(11): 1657-65, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689668
16.
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Br J Clin Pharmacol
; 73(1): 93-105, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21689142
17.
Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant.
Platelets
; 23(2): 106-15, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-21848368
18.
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Eur Heart J
; 32(7): 838-46, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21252171
19.
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.
Int J Toxicol
; 31(4): 317-25, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22692976
20.
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
JAMA
; 308(17): 1785-94, 2012 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23117779